Clexio Biosciences

We are a multi-asset, CNS-first clinical stage pharmaceutical company with a broad and growing pipeline. We are dedicated to developing novel therapies for patients suffering from neurological and psychiatric conditions. We are developing novel therapies to address patients’ unmet needs in Major Depressive Disorder, Chronic Pruritus of neurological origin, Neuropathic Pain, Cluster Headache and Parkinson ’s disease. Clexio Biosciences is a CNS-first clinical stage company. We are a multi-asset company with a rich and growing pipeline, from preclinical to Phase 2 development stages. Our multidisciplinary team brings years of experience in the Pharmaceutical and Biotech industries and encompasses end-to-end drug development expertise, from early stage to advanced clinical stages and regulatory approvals. Individually and as a team, we are excited every day to use our expertise to innovate, integrate, apply, and develop new and effective solutions for patients.